Search Results

Fauna Bio announced today Dr. Lara Do Amaral-Silva, assistant professor of biology at Wake Forest University, as the recipient of the FaunaBio Translational Research Award through the American Physiological Society (APS).

Fauna Bio announced today a preprint in BioRxiv that senior scientist Ryan J. Sprenger contributed during his PhD. and postdoctoral work which highlights the intricate mechanisms governing skeletal muscle metabolism during animal hibernation.

Fauna Bio, a biotechnology company that leverages animal genomics to improve human health, announces Senior Research Physiologist Ryan Sprenger, Ph.D., has been awarded a NASA Innovative Advanced Concepts grant.

Fauna Bio today announced a multi-year agreement with Eli Lilly and Company to apply Fauna’s Convergence™ artificial intelligence (AI) platform to support preclinical drug discovery efforts in obesity.

Eli Lilly has signed a multi-year contract with animal genomics biotech Fauna Bio to use its artificial intelligence platform to discover drug targets for obesity in a deal worth nearly half a billion dollars.

About a month after reporting it’s had a tough time starting enough patients on its treatments, bluebird bio announced it will lay off about 25% of its employees, over half of whom work in R&D.

With the addition of NTx’s co-founder and former President to the board Mercury Bio significantly enhances its strategic reach in the biotech sector

Fauna Bio, a biotechnology company pioneering the fields of comparative, computational and translational genomics, is celebrating its fourth birthday this month with the release of Centaur, a knowledge graph that is the first of its kind to visualize the intersection between animal gene expression data and human diseases in one comprehensive map.

Fauna Bio, a biotechnology company pioneering the fields of comparative, computational and translational genomics, announced a partnership with the University of Wisconsin OshKosh to accelerate the translation of human therapeutics discovered through research into extreme mammal adaptation.

Facing financial challenges, IN8bio is looking to preserve cash resources through a pipeline prioritization and layoffs at its New York City and Birmingham, Alabama, sites.